Recent health research highlights breakthroughs in diabetes and vitiligo treatments alongside studies on public health trends and substance use risks.

The drug upadacitinib shows long-term efficacy in treating nonsegmental vitiligo, with further improvement observed when combined with UVB phototherapy.

An investigational combination therapy of eloralintide and tirzepatide demonstrated significant efficacy in phase 2 trials, achieving up to 23.3% weight loss in patients with obesity and type 2 diabetes.

Clinical trial results indicate that orforglipron provides superior glycemic control and weight reduction in patients with type 2 diabetes while maintaining noninferiority for cardiovascular outcomes.

New research establishes a correlation between high county-level medical debt and an increased incidence of late-stage cancer across nine common types of the disease in the United States.

A decade-long study reveals a significant downward trend in the dispensing of benzodiazepines in the U.S., most notably among adults aged 18 to 29.

Data indicates that approximately 1 in 9 older adults in the U.S. who report using cannabis may suffer from cannabis use disorder.

Studies on psychedelic use show that while substances like psilocybin and LSD are more prevalent, users of ibogaine and 5-MeO-DMT report higher frequencies of serious adverse events like cardiac issues and suicidal ideation.

The age of onset for systemic lupus erythematosus (SLE) serves as a predictor for clinical trajectory, with juvenile-onset linked to relapse risks and late-onset associated with a higher likelihood of remission.